Does the media favor NVAX or RIGL?

In the previous week, Novavax had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Novavax's score of 0.24 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INVA or RIGL?

In the previous week, Innoviva had 6 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Innoviva's score of 0.09 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNKD or RIGL?

In the previous week, MannKind had 12 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 15 mentions for MannKind and 3 mentions for Rigel Pharmaceuticals. MannKind's average media sentiment score of 0.81 beat Rigel Pharmaceuticals' score of 0.64 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or ZBIO?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 3 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Zenas BioPharma's score of 0.64 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or OPK?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Rigel Pharmaceuticals' score of 0.64 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rigel Pharmaceuticals (RIGL) Competitors

$30.25 -0.05 (-0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$30.74 +0.49 (+1.63%)

As of 05:05 PM Eastern

Compare

RIGL vs. NVAX, INVA, MNKD, ZBIO, and OPK

Should you buy Rigel Pharmaceuticals stock or one of its competitors? MarketBeat compares Rigel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rigel Pharmaceuticals include Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), Zenas BioPharma (ZBIO), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Novavax has higher revenue and earnings than Rigel Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.49	$440.30M	-$0.58	N/A
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62

Rigel Pharmaceuticals has a net margin of 121.50% compared to Novavax's net margin of -14.73%. Rigel Pharmaceuticals' return on equity of 47.99% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

In the previous week, Novavax had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Novavax's score of 0.24 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.0% of Novavax shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 18.99%. Rigel Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 80.17%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Rigel Pharmaceuticals beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 63.36%. Rigel Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 80.17%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has a net margin of 121.50% compared to Innoviva's net margin of 119.89%. Rigel Pharmaceuticals' return on equity of 47.99% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

In the previous week, Innoviva had 6 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Innoviva's score of 0.09 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has lower revenue, but higher earnings than Innoviva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Innoviva on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, MannKind had 12 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 15 mentions for MannKind and 3 mentions for Rigel Pharmaceuticals. MannKind's average media sentiment score of 0.81 beat Rigel Pharmaceuticals' score of 0.64 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to MannKind's net margin of -6.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Rigel Pharmaceuticals has lower revenue, but higher earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$360.78M	3.01	$5.86M	-$0.07	N/A
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62

MannKind has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

MannKind presently has a consensus price target of $8.97, suggesting a potential upside of 154.79%. Rigel Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 80.17%. Given MannKind's stronger consensus rating and higher possible upside, research analysts plainly believe MannKind is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

49.5% of MannKind shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 3 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.64 beat Zenas BioPharma's score of 0.64 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to Zenas BioPharma's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Zenas BioPharma	N/A	-99.99%	-58.06%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 80.17%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 140.95%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Rigel Pharmaceuticals beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to OPKO Health?

Rigel Pharmaceuticals (NASDAQ:RIGL) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.90	$367.02M	$18.72	1.62
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 80.17%. OPKO Health has a consensus price target of $1.55, suggesting a potential upside of 6.16%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

Rigel Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.72 beat Rigel Pharmaceuticals' score of 0.64 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to OPKO Health's net margin of -36.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
OPKO Health	-36.63%	-16.78%	-10.98%

Summary

Rigel Pharmaceuticals beats OPKO Health on 12 of the 17 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$559.63M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	1.62	18.12	23.87	24.36
Price / Sales	1.90	303.59	521.52	117.07
Price / Cash	4.45	55.72	41.27	57.13
Price / Book	1.40	3.95	9.99	6.73
Net Income	$367.02M	$75.85M	$3.56B	$337.03M
7 Day Performance	0.67%	-1.13%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	47.27%	23.03%	28.77%	33.98%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	3.2469 of 5 stars	$30.25 -0.2%	$54.50 +80.2%	+48.6%	$559.63M	$294.28M	1.62	160	Analyst Forecast
NVAX Novavax	2.0344 of 5 stars	$10.51 -4.2%	$12.13 +15.4%	+40.5%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.3468 of 5 stars	$21.51 +0.4%	$36.20 +68.3%	+5.3%	$1.58B	$411.33M	3.58	100	Analyst Forecast Analyst Revision High Trading Volume
MNKD MannKind	4.1489 of 5 stars	$3.53 -6.4%	$8.97 +154.1%	-24.0%	$1.16B	$348.97M	N/A	400	Analyst Forecast
ZBIO Zenas BioPharma	3.6967 of 5 stars	$18.17 -1.3%	$44.29 +143.7%	+82.8%	$1.16B	N/A	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. NVAX, INVA, MNKD, ZBIO, and OPK

How does Rigel Pharmaceuticals compare to Novavax?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Rigel Pharmaceuticals compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. NVAX, INVA, MNKD, ZBIO, and OPK

How does Rigel Pharmaceuticals compare to Novavax?

Which has more risk and volatility, NVAX or RIGL?

Which has stronger valuation & earnings, NVAX or RIGL?

Is NVAX or RIGL more profitable?

Does the media favor NVAX or RIGL?

Do institutionals and insiders have more ownership in NVAX or RIGL?

Do analysts recommend NVAX or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Do analysts prefer INVA or RIGL?

Is INVA or RIGL more profitable?

Does the media favor INVA or RIGL?

Which has stronger earnings & valuation, INVA or RIGL?

Do institutionals & insiders have more ownership in INVA or RIGL?

Which has more volatility & risk, INVA or RIGL?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Does the media favor MNKD or RIGL?

Is MNKD or RIGL more profitable?

Which has better valuation & earnings, MNKD or RIGL?

Which has more volatility and risk, MNKD or RIGL?

Do analysts prefer MNKD or RIGL?

Do institutionals and insiders have more ownership in MNKD or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Which has more risk and volatility, RIGL or ZBIO?

Which has stronger earnings and valuation, RIGL or ZBIO?

Does the media favor RIGL or ZBIO?

Is RIGL or ZBIO more profitable?

Do insiders & institutionals hold more shares of RIGL or ZBIO?

Do analysts rate RIGL or ZBIO?

Summary

How does Rigel Pharmaceuticals compare to OPKO Health?

Do insiders and institutionals hold more shares of RIGL or OPK?

Which has stronger valuation & earnings, RIGL or OPK?

Do analysts recommend RIGL or OPK?

Which has more risk and volatility, RIGL or OPK?

Does the media favor RIGL or OPK?

Is RIGL or OPK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools